Brother Enterprises (SHE:002562) subsidiary Jiangxi Brother Pharmaceutical obtained the registration certificate for its iodixanol active pharmaceutical ingredient from India's Central Drugs Standard Control Organisation.
The certificate, valid until April 28, 2029, allows the company to officially market and sell the iodine contrast agent API in India, according to a Friday filing with the Shenzhen bourse.
Iodixanol is used as a contrast agent during coronary angiography.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.